RNF6 and non-small cell lung carcinoma: A notable example is the promotion of resistance to cisplatin in non-small cell lung cancer through TRIM17-mediated ubiquitination and degradation of RBM38 (Zhong et al. 2023);RNF6 promotes cisplatin resistance by transcriptionally activating the expression of proliferating cell nuclear antigens and attenuating DNA damage in lung adenocarcinoma (Sun et al. 2022).In addition, UBE2T promotes temozolomide resistance in glioblastoma by modulating the Wnt/β-catenin signaling pathway (Wang et al. 2023).